Wells Fargo Maintains Overweight on Globus Medical, Lowers Price Target to $99
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Larry Biegelsen maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $103 to $99.
Wells Fargo analyst Larry Biegelsen maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $103 to $99.